

Amendments to the Claims

This listing of claims will replace the originally filed claims in the application.

Listing of Claims:

Claims 1 – 15 (cancelled)

Claim 16 (new): The use of a gaseous mixture containing xenon gas and nitrous oxide gas to manufacture all or part of an inhalable medicament for preventing or treating a neurointoxication in man, the volume proportion of xenon being between 5% and 45% and the volume proportion of nitrous oxide being between 10% and 50%.

Claim 17 (new): The use as claimed in claim 16, characterized in that the neurointoxication results from a cerebral excess of one or more neurotransmitters.

Claim 18 (new): The use as claimed claim 16, characterized in that the mixture containing xenon and nitrous oxide acts on at least one cerebral receptor so as to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurine, GABA, noradrenalin and/or any other neurotransmitter.

Claim 19 (new): The use as claimed in claim 16, characterized in that the remainder of the gaseous mixture is oxygen.

Claim 20 (new): The use as claimed in claim 16, characterized in that the volume proportion of xenon is between 20% and 40% and the volume proportion of nitrous oxide is between 10% and 40%.

Claim 21 (new): The use as claimed in claim 16, characterized in that the volume proportion of xenon is between 20% and 32% and the volume proportion of nitrous oxide is between 20% and 40%, and preferably the volume proportions of xenon and of nitrous oxide are each about 30%.

Claim 22 (new): The use as claimed in claim 16, characterized in that the volume proportion of xenon is between 10% and 20% and the volume proportion of nitrous oxide is between 40% and 50%, and preferably the volume proportion of xenon is about 16% and the volume proportion of nitrous oxide is about 50%.

Claim 23 (new): The use as claimed in claim 16, characterized in that the medicament also contains oxygen, an oxygen/nitrogen mixture or air, and the gaseous mixture preferably consists of xenon and nitrous oxide, the remainder being oxygen.

Claim 24 (new): The use as claimed in claim 16, characterized in that the medicament is ready-to-use.

Claim 25 (new): The use as claimed in claim 16, characterized in that the neurointoxication is of the type giving rise to a state of addiction.

Claim 26 (new): A gaseous mixture containing from 5% to 35% by volume of xenon and from 10% to 50% by volume of nitrous oxide, as an inhalable medicament.

Claim 27 (new): The gaseous mixture as claimed in claim 26, characterized in that it also contains oxygen.

Claim 28 (new): The mixture as claimed in claim 26, characterized in that it consists of from 20% to 32% by volume of xenon and from 20% to 40% of nitrous oxide, the remainder being oxygen.

Claim 29 (new): The mixture as claimed in claim 25, characterized in that the volume proportions of xenon and of nitrous oxide are each about 30%.

Claim 30 (new): The mixture as claimed in claim 26, characterized in that it consists of from 10% to 20% by volume of xenon and from 45% to 50% of nitrous oxide, the remainder being oxygen, and preferably the volume proportion of xenon is about 16% and the volume proportion of nitrous oxide is about 50%.